Study of Tislelizumab (BGB-A317) Versus Placebo in Combination With Chemoradiotherapy in Participant With ESCC
Status:
Recruiting
Trial end date:
2023-10-30
Target enrollment:
Participant gender:
Summary
This is a phase 3, randomized, double-blind, placebo-controlled study to compare the efficacy
and safety of BGB-A317 versus P placebo with chemoradiotherapy in participants with Localized
Esophageal Squamous Cell Carcinoma.